| P50 | author | Floor Backes | Q38643301 |
| | Debra L. Richardson | Q39381053 |
| | David E. Cohn | Q39381089 |
| P2093 | author name string | David M O'Malley | |
| | Ritu Salani | |
| | Jeffrey M Fowler | |
| | Eric L Eisenhauer | |
| | Larry J Copeland | |
| | Georgia A McCann | |
| | Patrick S Rheaume | |
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| | Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study | Q28258045 |
| | Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer | Q33381373 |
| | CA125 response: can it replace the traditional response criteria in ovarian cancer? | Q34981128 |
| | A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer | Q36889085 |
| | Bevacizumab toxicities and their management in ovarian cancer | Q37415131 |
| | Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? | Q37728686 |
| | Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer | Q39941516 |
| | Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer | Q41740928 |
| | Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer | Q46135004 |
| | Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer | Q46892024 |
| | Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. | Q53642979 |
| | Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer | Q60997828 |
| | Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels | Q74619168 |
| | Bevacizumab in the treatment of ovarian cancer | Q81458262 |
| | Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study | Q81570219 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bevacizumab | Q413299 |
| | paclitaxel | Q423762 |
| | ovarian cancer | Q172341 |
| P304 | page(s) | 269-272 | |
| P577 | publication date | 2011-02-18 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. | |
| P478 | volume | 121 | |